Dr Katie Qureshi MD, PhD
Dr Katie Qureshi is Vice President of Clinical Affairs at HighLife Medical, a medtech company focussed on Trans-Catheter Mitral Valve Replacement (TMVR) with both trans-septal and trans-apical devices, where she is responsible for the global clinical trial strategy and operational execution. The technology is intended for the treatment of patients suffering from mitral valve regurgitation and is currently undergoing evaluation in feasibility studies in Europe. Most recently she headed the EMEA Medical Affairs team for the Interventional Cardiology &Structural Heart division at Boston Scientific for 5.5 years and previously worked for Cordis, Johnson &Johnson.
Katie received her medical degree from St Bartholomew’s Medical School, University of London and also holds a First Class Honours Bachelor’s degree in Immunology from UCL. She undertook her general medical and subsequent specialist cardiology training in various hospitals in London including The Hammersmith Hospital/Imperial College Postgraduate rotation, Guy’s Hospital, St Thomas’s, Royal Brompton and Harefield and the London Chest Hospital. Katie completed a period of postgraduate research in molecular biology at Oxford University, holds a PhD from The William Harvey Research Institute, University of London and has authored a number of journal articles and book chapters.